论文部分内容阅读
目的:研究支气管哮喘患者外周血中白细胞介素-19(IL-19)的水平及其临床意义。方法:选取42例支气管哮喘患者(22例为急性发作期,20例为缓解期)为研究对象,并以23例健康者为对照,采用酶联免疫吸附试验法(ELISA)检测所有患者的外周血IL-19水平,同时测定其第1秒用力呼气容积占预计值百分比(FEV1%),进行比较分析。结果:急性发作期组患者的外周血IL-19水平为(370.2±142.8)pg/mL,缓解期组为(403.9±160.6)pg/mL,均较对照组的(204.4±102.8)pg/mL明显增高,P<0.05,差异具有统计学意义;而急性发作期组外周血IL-19水平与缓解期组比较差异无统计学意义(P>0.05)。相关性分析显示,外周血IL-19水平与FEV1%无明显相关性(r=0.25,P>0.05)。结论:IL-19可能是支气管哮喘有价值的临床标志,并参与了哮喘气道炎症的形成。
Objective: To investigate the level of interleukin-19 (IL-19) in peripheral blood of patients with bronchial asthma and its clinical significance. Methods: Twenty-four patients with bronchial asthma (22 acute exacerbation and 20 remission) were selected as experimental subjects. Twenty-three healthy controls were used as controls. The peripheral blood samples of all patients were detected by enzyme-linked immunosorbent assay (ELISA) Blood IL-19 levels were measured at the same time, the first second forced expiratory volume accounted for the expected percentage (FEV1%), for comparative analysis. Results: The levels of IL-19 in the peripheral blood of the patients with acute exacerbation were (370.2 ± 142.8) pg / mL and (403.9 ± 160.6) pg / mL respectively, which were significantly higher than those of the control group (204.4 ± 102.8 pg / mL (P <0.05), while the difference was statistically significant. However, the level of IL-19 in peripheral blood in acute exacerbation group was not significantly different from that in remission group (P> 0.05). Correlation analysis showed no significant correlation between IL-19 level and FEV1% (r = 0.25, P> 0.05). Conclusion: IL-19 may be a valuable clinical marker for bronchial asthma and is involved in the formation of airway inflammation in asthma.